Abstract
Describe and analyze the evolution of the price and the cost of cancer treatments used in hospital in France, in addition to the benefits provided by homogeneous groups of stay. An analysis of treatments funded in French hospitals between 2010 and 2016 brings objective data. Coming waves of therapeutic innovations in oncology question price rationality and healthcare insurances budget sustainability. The part of anticancer drugs in the extra-DRG list budget is the same in 2016 than in 2010, mean weighted price is stable (12 318€) since 2012, entrance price has significantly increased (18 658 €) but this growth is logically due to the increase of the number of innovations and the decrease of target populations. The first interest of the study lies in the effort to objectify the prices and costs that, in french hospital, represent the anticancer treatments. The reported results contradict many misconceptions: the budget share of cancer drugs on the list is the same in 2016 as in 2010; the weighted average price of cancer treatments has been stable since 2012; at market entry, the price of cancer drugs has increased significantly since 2010, but this growth can be rationally explained by the increase in the number of innovations and the decrease in the size of the target populations, two criteria taken into account in the determination price. The additional funding requirements for new cancer treatments do not seem out of reach thanks to expected savings in economic regulation and the arrival of biosimilar drugs, but access issues invite to reconsider prices determination criterions and adapt funding modalities to the different types of innovation.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
